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Abstract
Background:  Aim of this study was to evaluate the correlation of inflammatory markers
procalcitonin (PCT), C-reactive protein (CRP) and leukocyte count (WBC) with microbiological
etiology of CAP.
Methods:  We enrolled 1337 patients (62 ± 18 y, 45% f) with proven CAP. Extensive
microbiological workup was performed. In all patients PCT, CRP, WBC and CRB-65 score were
determined. Patients were classified according to microbial diagnosis and CRB-65 score.
Results: In patients with typical bacterial CAP, levels of PCT, CRP and WBC were significantly
higher compared to CAP of atypical or viral etiology. There were no significant differences in PCT,
CRP and WBC in patients with atypical or viral etiology of CAP. In contrast to CRP and WBC, PCT
markedly increased with severity of CAP as measured by CRB-65 score (p < 0.0001). In ROC
analysis for discrimination of patients with CRB-65 scores > 1, AUC for PCT was 0.69 (95% CI 0.66
to 0.71), which was higher compared to CRP and WBC (p < 0.0001). CRB-65, PCT, CRP and WBC
were higher (p < 0.0001) in hospitalised patients in comparison to outpatients.
Conclusion: PCT, CRP and WBC are highest in typical bacterial etiology in CAP but do not allow
individual prediction of etiology. In contrast to CRP and WBC, PCT is useful in severity assessment
of CAP.
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Introduction
Several inflammatory markers, e.g. C-reactive protein
(CRP) and leukocyte count (WBC) are used in the diag-
nostics of pulmonary infections. However, they are unspe-
cific and not helpful for the differentiation of bacterial or
viral etiology of pneumonia [1-3]. Procalcitonin (PCT) is
a promising alternative in this regard. It rapidly increases
in bacterial infections but remains low in viral diseases.
High plasma concentrations of PCT are typically seen in
sepsis, meningitis and pneumonia [4-9]. PCT also seems
to be a prognostic factor in sepsis or pneumonia [10-12].
Since June 2002 the German competence network CAP-
NETZ, funded by the Federal Ministry of Education and
Research, samples data from inpatients and outpatients
with CAP. CAPNETZ incorporates ten local clinical centres
(LCC) spread over Germany. More information about
CAPNETZ is available on the website http://www.cap
netz.de[13]. This framework offers a good opportunity to
study the value of inflammatory markers in the etiological
diagnosis of CAP.
Thus, the aim of our study was to investigate whether
inflammatory markers at admission are helpful to predict
the microbiological etiology in CAP patients.
Methods
Patients
Within CAPNETZ all new CAP cases are reported via a net-
work of sentinel practices and hospitals to the study mon-
itor of the corresponding local clinical centre (LCC). The
study monitor of the LCC includes the patient in CAP-
NETZ by applying the following criteria: age ³ 18 years, a
pulmonary infiltrate diagnosed by chest x-ray, clinical
symptoms consisting of cough or purulent sputum or pos-
itive auscultation. Exclusion criteria are age < 18 years,
acquired or therapeutically induced immune deficiency,
florid tuberculosis or a possible nosocomial genesis of
infection (hospitalisation less than four weeks prior to
infection). After inclusion in CAPNETZ all clinical param-
eters of the patients are stored in an electronic database.
CAP patients of ten LCC were included. Written informed
consent was obtained from every patient prior to inclu-
sion in the study. The study was approved by the local eth-
ical committee. Our study was not an intervention study
with implementation of standardized criteria for the diag-
nosis and therapy of CAP according to guidelines, biomar-
ker levels or CRB-65 score.
Microbiological diagnostics
At the point of inclusion into the study blood samples
were taken for the determination of PCT, CRP and WBC,
blood culture and serological testing for Chlamydia pneu-
moniae and Mycoplasma pneumoniae. Sputum samples and
pharyngeal aspiration were taken from every patient
whenever possible to test for bacteria and viruses accord-
ing to standard procedures. Urine samples were collected
and tested whenever possible for Legionella pneumophila
and Streptococcus pneumoniae with an antigen test.
Sputum was Gram stained. Representative sputum origi-
nating from the lower respiratory tract was validated by
the criteria > 25 granulocytes and < 10 epithelial cells per
low power field (total magnification × 100). Validated
sputum, blood culture samples and undiluted and serially
diluted tracheobronchial aspirates were plated on the fol-
lowing media: blood-sheep agar, CDC agar, chocolate
agar as well as Sabouraud agar. Urine was tested for the
presence of Streptococcus pneumoniae and Legionella spp.
antigen. Identification of microorganisms and susceptibil-
ity testing was performed according to standard methods.
Infectious etiology of pneumonia was classified as defi-
nite if one of the following criteria were met: 1) blood cul-
tures yielding a bacterial or fungal pathogen (in the
absence of an apparent extrapulmonary focus); 2) trache-
obronchial secretions: at least ++ growth of one of the spe-
cies defined as pathogens; 3) a valid sputum sample
(leukocytes 25 per 10× field) yielded one or more pre-
dominant bacterial pathogens or 3+ growth. The follow-
ing species were regarded as potential pathogens:
Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella
pneumoniae, Escherichia coli and other enterobacterial spe-
cies, Pseudomonas aeruginosa, Moraxella catarrhalis, Steno-
trophomonas maltophilia; 4) Chlamydia pneumoniae: (IgM ³
1:32) and/or PCR positive in at least two different labora-
tories; 5) Legionella: bacterial growth in respiratory secre-
tions or detection of urinary antigen or detection of
legionella specific DNA by PCR; 6) Mycoplasma pneumo-
niae: PCR positive; 7) bacterial growth in cultures of TBAS
³ 105 cfu/ml; 8) positive urinary antigen for Streptococcus
pneumoniae; 9) PCR positive for Influenzavirus A and B,
RS-Virus, Adenovirus, Enterovirus. 10) Aspergillus spp.
were accepted as definite in the presence of concomitant
lung abscess and/or histologic confirmation. Candida
albicans was only accepted as the causative agent if it
occurred in high numbers in purulent sputum (25 and
more leukocytes per field).
Determination of PCT, CRP and leukocyte count
Leukocyte count (WBC) was determined by the hospital
laboratory. Serum CRP was measured by nephelometry
with a commercially available assay (Behring Diagnostics,
Marburg, Germany). Serum PCT was determined by an
immunofluorescent assay (B.R.A.H.M.S PCT sensitive
KRYPTOR, B.R.A.H.M.S AG, Henningsdorf, Germany). All
serum samples for PCT testing were centrally stored at -
70°C in the LCC Ulm until measurement. The assay
requires 50 ml of serum, EDTA or heparin plasma, has a
functional assay sensitivity (defined as lowest value with
an interassay CV <20%) of 0.06 ng/mL and a lower detec-
tion limit of 0.02 ng/mL. Laboratory measurements wereRespiratory Research 2009, 10:65 http://respiratory-research.com/content/10/1/65
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performed in a blinded fashion without knowledge of the
microbiological results.
Determination of CRB-65
The CRB-65 score consists of four variables: confusion,
respiratory rate ³ 30/min, systolic blood pressure < 90
mm Hg or diastolic blood pressure £  60 mmHg, age ³ 65
years [14,15]. One point is given for each parameter
present which results in CRB-65 scores of 0–4. For each
patient the CRB-65 score was calculated with patient data
ascertained at first presentation.
Statistics
We performed statistical analysis with Graph Pad Prism
4.0 and tested distribution with the Kolmogorov-Smirnov
test. Two group comparisons of nonparametric data were
performed by the Mann-Whitney U-test. For multigroup
comparisons, Kruskal-Wallis one-way analysis of variance
test was used. Frequency comparison was done using the
c2-test. We constructed Receiver-operating-characteristics
(ROC) curves using MedCalc statistical software and
determined the area under the curve (AUC). All statistical
tests were 2-tailed and a p-value < 0.05 was considered sta-
tistically significant.
Results
Patients
In 1337 patients mean age was 62 ± 18 years (range 18 to
98 years), and 55% were male. The causative pathogen
was identified in 472 patients (35.3%) [typical bacterial
infection: n = 185, atypical bacterial infection n = 190,
viral infection n = 39; mixed infections with two or more
pathogens (n = 58) including the following combina-
tions: two or more typical or atypical bacteria, typical bac-
terial plus atypical bacterial infection, typical or atypical
bacterial infection plus viruses]. Organisms included in
the definition of bacterial pneumonia and pneumonia
caused by atypical pathogens and viruses are shown in
table 1. 898 patients (67.2%) were hospitalised, 439
(32.8%) were outpatients.
The etiologic distribution of the causative pathogens is
summarized in table 1. Patients with proven typical bacte-
rial etiology showed significantly higher PCT levels (figure
1a), CRP levels (figure 1b) and WBC (figure 1c) compared
to patients with atypical or viral etiology. A PCT cut-off
level of 0.1 ng/mL showed an odds ratio of 8.3 (95% CI
4.8 to 14.5) and a cut-off level of 0.25 ng/mL an odds
ratio of 3.2 (95% CI 2.1 to 5.0) to differentiate S. pneumo-
niae CAP from CAP due to atypical or viral etiology. Levels
of PCT, CRP and WBC were comparable in patients with
atypical or viral etiology.
CRB-65 score
The severity of pneumonia was assessed using the CRB-65
score. Overall, the mean CRB-65 score was 0.96 ± 0.88
ranging from class 0 to 4 (class 0, n = 416; class 1, n = 497;
class 2, n = 240, class 3, n = 46; class 4, n = 10). The distri-
bution of the CRB-65 scores was comparable in patients
with CAP due to typical bacterial etiology (mean CRB-65
score: 0.98 ± 0.92), atypical bacterial etiology (mean: 0.79
± 0.84), viral (mean: 1.10 ± 0.85), "mixed" (mean: 0.98 ±
0.92) or unknown etiology (mean: 0.97 ± 0.87).
Correlation of PCT, CRP and WBC to CRB-65 class
Median levels of PCT, CRP and WBC were calculated
according to CRB-65 severity class. PCT levels increased
with increasing severity of CAP (p < 0.0001, figure 2a).
Median PCT value was 0.10 ng/mL (range 0.002 to 43.31
ng/mL) in CRB-65 class 0; 0.15 ng/mL (range, 0.01 to
250.22 ng/mL) in class 1; 0.31 ng/mL (range, 0.03 to
100.00 ng/mL) in class 2; 0.70 ng/mL (range, 0.04 to
30.00 ng/mL) in class 3; and 3.33 ng/mL (range, 0.24 to
15.45 ng/mL) in class 4. Median PCT levels in patients
with non-severe CAP (defined as CRB-65 class 0–1) were
significantly lower (0.12 ng/mL) as compared to patients
with severe CAP (defined as CRB-65 class 2–4; 0.36 ng/
mL, p < 0.0001). In 410 patients PCT levels were < 0.1 ng/
mL. These patients were classified into lower CRB-65
classes (mean 0.62 ± 0.72) compared to those patients
with PCT levels ³ 0.1 ng/mL (mean 1.13 ± 0.90, p <
0.0001). The distribution of CRP values is shown in figure
2b. Only a moderate increase with the severity of CAP
could be observed. The CRB-65 classes 0 and 2 showed a
significant difference in their CRP levels (p < 0.01), all
other groups showed no significant difference. There was
a significant difference (p = 0.0037) between median CRP
values in patients classified into CRB-65 risk classes 0 and
1 (78.0 mg/L; 0.00 mg/mL – 634.00 mg/mL) and patients
classified into CRB-65 classes 2–4 (118.0 mg/L; 0.50 mg/
mL – 580.00 mg/mL)
Figure 2c shows the distribution of WBC in different CRB-
65 classes. Median WBC in patients with non-severe CAP
(defined as CRB-65 class 0–1) (10.9 G/L; 2.10 G/L – 43.20
G/L) was significantly (p = 0.0002) lower as compared to
patients with severe CAP (defined as CRB-65 class 2–4;
12.05 G/L, 2.10 G/L – 49.60 G/L).
Receiver operating characteristic curves illustrate the accuracy
of PCT, CRP and WBC to predict severe CAP (defined as
CRB-65 > 1). The AUC for PCT was 0.69 (95% CI 0.66 to
0.71) demonstrating fair to good discriminatory power. At a
cut-off level of 0.1 ng/mL an odds ratio of 3.7 (95% CI 2.6 to
5.2) was calculated for the prediction of severe CAP. The
AUCs for CRP (0.57, 95% CI 0.54 to 0.60) and WBC (0.56,
95% CI 0.53 to 0.590) were significantly lower (p < 0.0001)
and demonstrated poor discriminatory power.
Outpatients and hospitalised CAP patients
Outpatients were classified into lower CRB-65 classes
(mean 0.43 ± 0.57) compared to hospitalised patientsRespiratory Research 2009, 10:65 http://respiratory-research.com/content/10/1/65
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(mean 1.20 ± 0.89, p < 0.0001). Median PCT, CRP, and
WBC values were significantly higher in hospitalised
patients compared to outpatients. In ROC curve analysis
where sensitivity was calculated among those patients
who were hospitalised and specificity was assessed among
patients who were treated as outpatients the AUC for CRB-
65 was 0.74 (95% CI 0.72 to 0.77) demonstrating good
discriminatory power. For PCT, AUC was significantly
higher (0.79, 95% CI 0.76 to 0.81, p = 0.02). At a cut-off
level of 0.1 ng/mL an odds ratio of 6.8 (95% CI 5.3 to 8.8)
was calculated for the prediction of hospitalisation. The
AUCs for CRP (0.73, 95% CI 0.71 to 0.76, p < 0.001) and
WBC (0.70, 95% CI 0.68 to 0.73, p < 0.001) were signifi-
cantly lower compared to PCT.
Atypical pathogens
In the study population we identified 48 patients with
Legionella pneumophila, 140 with Mycoplasma pneumoniae
and only two patients with Chlamydia pneumoniae. In
patients with CAP caused by Legionella pneumophila, Myco-
plasma pneumoniae or Chlamydia pneumoniae, (Figure 3)
there were no significant differences in PCT (0.20 ng/mL;
0.02 ng/mL – 41.77 ng/mL vs. 0.10 ng/mL; 0.01 ng/mL –
12.14 ng/mL vs. 0.03 ng/mL; 0.02 ng/mL – 0.04 ng/mL,
n.s.), CRP (76.00 mg/mL; 0.50 mg/mL – 580.00 mg/mL
vs. 74.75 mg/mL; 0.80 mg/mL – 480.00 mg/mL vs. 113.5
mg/mL; 3.00 mg/mL – 224.00 mg/mL, n.s.) and WBC
(12.00 G/L; 2.80 G/L – 32.60 G/L vs. 10.70 G/L; 2.3 G/L
– 28.40 G/L vs. 8.05 G/L; 5.1 G/L – 11.00 G/L, n.s.).
Table 1: Causative microorganisms in CAP patients
Etiology Total Inpatients Outpatients
Typical bacterial pathogens 185 (13.8%) 139 (10.4%) 46 (3.4.%)
S. pneumoniae 122 (9.1%) 95 (7.1%) 27 (2.0%)
H. influenzae 13 (1.0%) 8 (0.6%) 5(0.4%)
Haemophilus spp 2 (0.1%) 1 (0.1%) 1 (0.1%)
E. coli 9 (0.7%) 7 (0.5%) 2 (0.1%)
S. aureus 12 (0.9%) 8 (0.6%) 4 (0.3%)
Moraxella catarrhalis 5 (0.4%) 1 (0.1%) 4 (0.3%)
Enterobacter spp. 5 (0.4%) 5 (0.4%) 0
Proteus mirabilis 2 (0.1%) 2 (0.1%) 0
Pseudomonas spp. 1 (0.1%) 1 (0.1%) 0
Pseudomonas aeruginosa 1 (0.1%) 1 (0.1%) 0
Citrobacter spp 2 (0.1%) 0 2 (0.1%)
Enterococcus faecium 1 (0.1%) 1 (0.1%) 0
Klebsiella pneumonite 2 (0.1%) 2 (0.1%) 0
Klebsiella oxytoca 1 (0.1%) 1 (0.1%) 0
Streptococcus agalactiae 4 (0.3%) 3 (0.2%) 1 (0.1%)
Streptococcus pyogenes 1 (0.1%) 1 (0.1%) 0
Streptococcus acidominimus 1 (0.1%) 1 (0.1%) 0
Prevotella spp. 1 (0.1%) 1 (0.1%) 0
Atypical pathogens 190 (14.2%) 115 (8.6%) 75 (6.6%)
M. pneumoniae 140 (10.5%) 80 (6.0%) 60 (4.5%)
Legionella spp 48 (3.6%) 34 (2.5%) 14 (1.0%)
Chl. pneumoniae 2 (0.1%) 1 (0.1%) 1 (0.1%)
Viruses 39 (2.9%) 25 (1.9%) 14 (1.0%)
Adenovirus 2 (2.2%) 2 (0.1%) 14 (1.0)
Influenza A 33 (2.5%) 19 (1.4%) 0
RS Virus 3 (0.2%) 3 (0.2%) 0
Enterovirus 1 (0.1%) 1 (0.1%)
Mixed 58 (4.3%) 42 (3.1%) 16 (1.2%)
Unknown 865 (64.7%) 577 (43.2%) 288 (21.5%)
Total 589 (100%) 384 (100%) 205 (100%)
Data are presented as number of cases (percentages of total number)Respiratory Research 2009, 10:65 http://respiratory-research.com/content/10/1/65
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Discussion
The current study demonstrated that a) PCT, CRP and
WBC values are significantly higher in CAP due to classical
bacterial pathogens compared to atypical bacterial or viral
pneumonia, b) PCT levels increase with an increasing
CRB-65 score as a marker of the severity of CAP and c)
PCT levels and CRB-65 score show a comparable power to
detect CAP patients that will be hospitalised, whereas CRP
or WBC have very poor discriminatory power in this
point.
In CAP it is essential to assess disease severity to optimise
therapeutic decisions, e.g. about hospitalisation, ICU
admission and choice of antibiotic treatment [14-18]. Dif-
ferent scoring systems have been developed for a more
objective assessment of CAP severity. Based on the modi-
fied severity assessment score of the British Thoracic Soci-
ety [14] the simple CURB score was developed [15]. In a
primary care setting blood urea results are not directly
available. Therefore the CURB score has been modified to
the CRB-65 score that includes only clinical variables.
Blood urea is excluded and instead age ³ 65 years is used
as a variable. Risk assessment by the CRB-65 score yielded
in results equal to the CURB score in CAP patients [19].
CAP patients with a CRB-65 score of 0–1 have a very low
mortality risk and can be treated as outpatients [20].
Patients with a CRB-65 score of ³ 2 are at intermediate
(score 2) or high risk (score 3–4) and should be treated in
hospital. In our study, CRB-65 score was significantly
lower in outpatients but was not influenced by the micro-
biological etiology of CAP. In a former study of our group
we could demonstrate that PCT levels on admission pre-
dict the severity and outcome of CAP with a similar prog-
nostic accuracy as the CRB-65 score and a higher
prognostic accuracy compared to WBC and CRP [12].
Admission levels of PCT (a), CRP (b) and WBC (c) in CAP patients with classical bacterial, atypical, viral, "mixed" or unknown  etiology Figure 1
Admission levels of PCT (a), CRP (b) and WBC (c) in CAP patients with classical bacterial, atypical, viral, 
"mixed" or unknown etiology. The scatterplots represent all data. Median values with interquartile ranges are shown. ns = 
no significant difference; n.d. = unknownRespiratory Research 2009, 10:65 http://respiratory-research.com/content/10/1/65
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To our knowledge, this is the largest study to date per-
formed in adults with CAP in which PCT and CRP serum
levels and WBC have been evaluated in all patients. A
detailed analysis of the correlation of these inflammatory
markers with CRB-65 score has not been performed in a
larger CAP population before. In a recently published
study, Masia et al. found that PCT contribution to the
evaluation of patients with CAP varies according to sever-
ity of pneumonia [11]. The authors described no differ-
ences in PCT levels between major etiologic groups when
the whole sample of patients with CAP was considered.
However, when patients were stratified according to PSI
score, the highest PCT levels tended to predict bacterial
etiology in patients with a low PSI score (risk classes I and
II). No differences in PCT levels were found between
major etiologic groups in patients with higher PSI scores
(risk classes III-V). CRP values were not reported in this
study. In contrast to the study by Masia et al. we found sig-
nificantly higher PCT levels in classical bacterial CAP
compared to atypical bacterial or viral pneumonia. This
might be explained by the higher number of patients that
were evaluated in our study (1337 vs. 185 patients), so
that the sample size in the different etiologic groups was
higher, which resulted in a higher statistical power.
Our study confirms the findings of previous studies that
PCT is a good predictor of severity of pneumonia
[8,10,11,21]. Patients with a higher CRB-65 score had sig-
nificantly higher PCT levels. The discriminatory power of
the CRB-65 score and PCT for the prediction of hospitali-
sation of CAP patients was comparable. A PCT level > 0.1
ng/mL constitutes a 3.7-fold higher risk to suffer from
severe CAP (defined as CRB-65 score >1) and a 6.8-fold
higher risk to be hospitalised. CRP and WBC were not
helpful for the discrimination of low risk and high risk
patients and the prediction of hospitalisation.
Admission levels of PCT (a), CRP (b) and WBC (c) in CAP patients classified into CRB-65 classes 0–4 Figure 2
Admission levels of PCT (a), CRP (b) and WBC (c) in CAP patients classified into CRB-65 classes 0–4. The scat-
terplots represent all data. Median values with interquartile ranges are shown. Results of Kruskal-Wallis one-way analysis of 
variance are shown. ns = no significant difference.Respiratory Research 2009, 10:65 http://respiratory-research.com/content/10/1/65
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CAP can have various etiologies. In our study, classical
and atypical bacteria were the most frequent pathogens in
CAP. The distribution of pathogens in our study was com-
parable to a previous study including patients with severe
CAP [22]. We found significantly higher PCT, and CRP
concentrations as well as WBC in patients with classical
bacterial compared to atypical bacterial CAP. In contrast
to CRP and WBC, PCT may have one very important
potential – it might be a marker for clinically relevant
infections and could be used to decide if antibiotic treat-
ment should be initiated or not [23,24]. Antibiotic use
might be discouraged in patients with low PCT levels (e.g.
< 0.1 ng/mL). In a randomised controlled study with
patients with lower respiratory tract infections, the use of
antibiotics could be reduced by PCT guided therapy by
50% without any negative impact on clinical outcome
[23]. In a second randomised trial, Christ-Crain et al.
studied PCT guided antibiotic therapy in patients with
CAP [24]. Antibiotic therapy was discouraged if PCT was
< 0.25 ng/mL. As a result, PCT guided therapy signifi-
cantly reduced total antibiotic exposure, antibiotic pre-
scription on admission and antibiotic treatment duration
compared to treatment according to current guidelines.
The important effect of this study on clinical management
of CAP patients, treatment costs and development of
microbiological resistance has to be taken into account.
The results of the study by Christ-Crain et al. can be par-
tially explained by our findings. We could demonstrate
that CAP patients with lower severity of disease had signif-
icantly lower PCT levels. In conclusion, patients with
lower severity of disease might probably need less inten-
sive antibiotic therapy. A PCT cut-off level of 0.1 ng/mL
showed an odds ratio of 8.3 to differentiate S. pneumoniae
CAP from CAP due to atypical or viral etiology. However,
it was not possible to definitively differentiate between
CAP due to S. pneumoniae or other etiologies, so that a sin-
Admission levels of PCT (a), CRP (b) and WBC (c) in CAP patients with pneumococcal and atypical etiology of CAP Figure 3
Admission levels of PCT (a), CRP (b) and WBC (c) in CAP patients with pneumococcal and atypical etiology of 
CAP. The scatterplots represent all data. Median values with interquartile ranges are shown. ns = no significant difference.Respiratory Research 2009, 10:65 http://respiratory-research.com/content/10/1/65
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gle PCT measurement at admission seems not allow the
decision to prescribe a small or broad spectrum antibiotic.
CAP with viral or atypical etiology showed comparable
levels of inflammatory biomarkers, so that a differentia-
tion of both etiologies and the consecutive choice to start
antibiotic therapy was not possible in the individual
patient. Furthermore, there is the dilemma that higher
PCT levels are indicative of S. pneumoniae etiology on the
one hand but also of more severe CAP on the other hand.
PCT levels in our study are lower than those reported in
other studies including patients with lower respiratory
tract infections [23] or CAP [10,25]. This could be
explained by the fact, that these previous studies included
hospitalised patients in contrast to our study with a per-
centage of 32.8% outpatients. Although approximately
80% of CAP patients are not hospitalised, data for CAP
outpatients is very rare. Thus, one important goal of the
CAPNETZ study is to collect representative data about
outpatients. The severity of disease in outpatients is usu-
ally lower, which could be demonstrated by a lower CRB-
65 score in this group. As a consequence, these less severe
ill CAP patients show lower values of PCT. In other studies
that also included CAP outpatients, PCT levels were lower
and comparable with our results [8,26].
CRP is an early sensitive but non-specific marker of
inflammation. Long ago, CRP was initially discovered as a
test for patients with pneumococcal pneumonia [27].
Interestingly, there is only limited data on CRP in larger
studies including CAP patients. In one small study with 28
patients it could be demonstrated that serial CRP meas-
urements are helpful for the prediction of antibiotic treat-
ment failure or the development of infective
complications [28]. Patients with high CRP levels show a
longer duration of fever, longer hospital stay, and recover
less often after discharge, but CRP is not associated with a
higher mortality [29]. One recent study suggested higher
CRP levels in Legionella pneumophila infection but found
no correlation of CRP to the severity of the disease as
measured by the PSI score [30]. This corresponds with our
results showing no increase in CRP concentrations with
the severity of CAP as measured by the CRB-65 score. In
pediatric patients, serum CRP was not useful to distin-
guish between classical bacterial, atypical or viral pneu-
monia [2,31]. In contrast, Almirall et al. found in 201
patients with CAP higher levels of CRP in case of an infec-
tion by S. pneumoniae and Legionella pneumophila com-
pared to other infectious agents [32]. Almirall et al. also
described significantly lower CRP values in outpatients
than hospitalised patients. In our study group, CRP levels
of outpatients were lower compared to inpatients, too.
The same holds true for PCT and WBC, which both were
significantly lower in outpatients in our study.
The present study has some limitations. Despite intensive
microbiological diagnostics, the etiology remained
unknown in 64.7%. This low sensitivity of microbiologi-
cal tests is well known from other pneumonia studies. The
etiology of CAP has been studied in various patient popu-
lations, regions, settings and with different diagnostic
methodologies. A constant finding is the failure to detect
a pathogen in up to 60% of cases of hospitalized patients
with CAP [14,33,34]. There are several factors that may
reduce the diagnostic yield in our study as well as in the
previous ones. First, ambulatory antimicrobial pre-treat-
ment is very important. Nearly one third of patients are
pre-treated with antibiotics on hospital admission. Fang
et al. clearly showed the decline in diagnostic yield in the
presence of antibiotic pre-treatment [35]. Many cases of
unknown etiology may be caused by Streptococcus pneumo-
niae, a pathogen which is easily missed after one single
dose of antimicrobial treatment [36]. A second factor
might be that Mycoplasma pneumoniae and  Chlamydia
pneumoniae might be often not recognised due to diagnos-
tic problems, but represent important causes of CAP.
Third, another point that could explain the low number of
patients with a microbiological diagnosis is the fact that
32.8% of our patients included were outpatients. Outpa-
tients are usually less severely ill. The percentage of outpa-
tients that present with representative sputum or
bacteraemia that increase diagnostic yield is lower com-
pared to patients that are hospitalized. An important con-
founder which may have accounted for a large part of the
undiagnosed cases is incomplete diagnostic work-up,
especially in outpatients. A more extensive and aggressive
diagnostic approach may have increased the diagnostic
yield. However, even when using a most comprehensive
diagnostic approach the diagnostic yield is at maximum
70–80% [14,33]. The CAPNETZ study is a huge popula-
tion based study that includes outpatients and inpatients.
The application of more invasive procedures such as bron-
choscopy including bronchial washing and brushing is
not feasible and realistic in such a study and was therefore
omitted. Interestingly, it was previously shown that mor-
tality is not different between patients with and without
known etiology of CAP [37].
In conclusion, appropriate tools for establishing micro-
bial diagnosis and assessing severity of disease in CAP
would be helpful for optimal management of this disease.
Measurement of PCT, CRP, and WBC may be useful to
predict typical bacterial pneumonia, since elevated levels
were observed in comparison to atypical bacterial and
viral pneumonia. However, the inflammatory markers do
not allow an individual prediction of microbial etiology
of CAP. PCT might be a valuable tool helping clinicians –
in combination with scoring systems- to identify clinically
relevant infections, to assess a patient's risk profile, and toRespiratory Research 2009, 10:65 http://respiratory-research.com/content/10/1/65
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improve therapeutic decision making as well as decisions
about hospitalisation and ICU admission.
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